Journal article Open Access

Entecavir Induced Severe Myopathy: An Uncommon Side Effect

Tanoğlu, Alpaslan; Sarı, Oktay

Abstract

Chronic Hepatitis B virus (HBV) infection is a chronic viral illness that affects millions of people around the world and can cause serious consequences such as hepatic failure and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analog (NA), is a commonly used and generally safe therapeutic agent in HBV infection. In this paper, we aimed to present a case of chronic HBV that developed severe myopathy as an extremely rare side effect after the use of entecavir. Patients receiving entecavir therapy for chronic HBV should be closely monitored for the development of myopathy as well as other known and common side effects.

Özet

Kronik Hepatit B virusu (HBV) enfeksiyonu, dünya çapında milyonlarca insanı etkileyen ve karaciğer yetmezliği ve hepatoselüler karsinoma gibi ciddi sonuçlara neden olabilen kronik viral bir hastalıktır. Bir guanozin nükleozit analoğu (NA) olan entekavir, HBV enfeksiyonunda yaygın olarak kullanılan ve genellikle güvenli bir terapötik ajandır. Bu yazıda, entekavir kullanımından sonra son derece nadir bir yan etki olarak şiddetli miyopati gelişen bir kronik HBV olgusunu sunmayı amaçladık. Kronik HBV için entekavir tedavisi alan hastalar, miyopati gelişimi ve diğer bilinen ve yaygın yan etkiler açısından yakından izlenmelidir.

Entekavir ile İndüklenen Şiddetli Miyopati: Nadir Bir Yan Etki
Files (171.4 kB)
Name Size
26.JMVI-2021-2.1;15-17.pdf
md5:94e59f7c027a0247cf916dd9bacda904
171.4 kB Download
  • 1. Wilkins T, Sams R, Carpenter M. Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. Am Fam Physician 2019; 99(5): 314-23.

  • 2. Karagoz E, Tanoglu A. Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection. Hepat Mon 2017; 17(4): e12293.

  • 3. Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther 2015; 41(3): 310-9.

  • 4. Tu T, Douglas MW. Hepatitis B Virus Infection: From Diagnostics to Treatments. Viruses 2020; 12(12): 1366.

  • 5. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015; 51(5): 638-56.

  • 6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354(10): 1001-10.

  • 7. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat 2011; 18(12): 892-6.

  • 8. Yuan K, Guochun W, Huang Z, Lin B, Zhou H, Lu X. Entecavir-associated myopathy: a case report and literature review. Muscle Nerve 2014; 49(4): 610-4.

  • 9. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci U S A 2001; 98(5): 2284-8.

  • 10. Bridges EG, Jiang Z, Cheng YC. Characterization of a dCTP transport activity reconstituted from human mitochondria. J Biol Chem 1999; 274(8): 4620-5.

39
43
views
downloads
Views 39
Downloads 43
Data volume 7.4 MB
Unique views 35
Unique downloads 41

Share

Cite as